您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定
收藏 | 浏览56 | 下载8

Background::Non-communicable chronic diseases have become the leading causes of disease burden worldwide. The trends and burden of "metabolic associated fatty liver disease" (MAFLD) are unknown. We aimed to investigate the cardiovascular and renal burdens in adults with MAFLD and non-alcoholic fatty liver disease (NAFLD).Methods::Nationally representative data were analyzed including data from 19,617 non-pregnant adults aged ≥20 years from the cross-sectional US National Health and Nutrition Examination Survey periods, 1999 to 2002, 2003 to 2006, 2007 to 2010, and 2011 to 2016. MAFLD was defined by the presence of hepatic steatosis plus general overweight/obesity, type 2 diabetes mellitus, or evidence of metabolic dysregulation.Results::The prevalence of MAFLD increased from 28.4

作者:Zhang Hao-Jie;Wang Yu-Ying;Chen Chi;Lu Ying-Li;Wang Ning-Jian

来源:中华医学杂志英文版 2021 年 134卷 13期

知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求,方便快速、便捷的获取实用的医学信息,辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍
热门关注
免责声明:本知识库提供的有关内容等信息仅供学习参考,不代替医生的诊断和医嘱。

收藏
| 浏览:56 | 下载:8
作者:
Zhang Hao-Jie;Wang Yu-Ying;Chen Chi;Lu Ying-Li;Wang Ning-Jian
来源:
中华医学杂志英文版 2021 年 134卷 13期
标签:
Cardiovascular disease Chronic kidney disease Risk Metabolic associated fatty liver disease Non-alcoholic fatty liver disease Cardiovascular disease Chronic kidney disease Risk Metabolic associated fatty liver disease Non-alcoholic fatty liver disease
Background::Non-communicable chronic diseases have become the leading causes of disease burden worldwide. The trends and burden of "metabolic associated fatty liver disease" (MAFLD) are unknown. We aimed to investigate the cardiovascular and renal burdens in adults with MAFLD and non-alcoholic fatty liver disease (NAFLD).Methods::Nationally representative data were analyzed including data from 19,617 non-pregnant adults aged ≥20 years from the cross-sectional US National Health and Nutrition Examination Survey periods, 1999 to 2002, 2003 to 2006, 2007 to 2010, and 2011 to 2016. MAFLD was defined by the presence of hepatic steatosis plus general overweight/obesity, type 2 diabetes mellitus, or evidence of metabolic dysregulation.Results::The prevalence of MAFLD increased from 28.4